Physician

Alpana A Desai, M.D.

According to 2025 Medicare claims, Alpana Desai, M.D. (NPI: 1477504223) practices hematology/oncology in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from Martin, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34994-2236.

Desai's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,050 traditional Medicare patients, billed 514,761 HCPCS/CPT codes, and received $10,601,739 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,032 prescription claims across 366 beneficiaries totaling $4,678,515 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 48 claims. Open Payments data shows 212 records totaling $92,433. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $3,462,175 to $10,601,739. Similarly, Part D prescription costs have risen steadily, from $1,698,147 to $4,678,515. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,901 to $1,678.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	780	422,703	$3,462,175
2016	821	502,805	$5,252,194
2017	708	293,513	$4,476,274
2018	674	361,684	$4,654,599
2019	750	455,581	$5,643,989
2020	755	423,228	$6,105,857
2021	789	412,548	$5,942,994
2022	983	447,024	$6,091,298
2023	1,073	563,853	$9,620,887
2024	1,050	514,761	$10,601,739

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	354	1,801	$1,698,147
2016	349	2,015	$2,201,180
2017	308	1,591	$2,166,682
2018	242	1,613	$2,950,442
2019	270	1,622	$2,918,700
2020	294	1,777	$2,698,018
2021	291	1,875	$3,502,470
2022	315	1,490	$3,559,075
2023	340	1,724	$3,700,595
2024	366	2,032	$4,678,515

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	126	$10,515
2016	N/R	49	$1,585
2017	N/R	12	$185
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	23	114	$7,934
2021	N/R	98	$5,926
2022	N/R	101	$3,193
2023	N/R	14	$1,939
2024	N/R	48	$832

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	861	2,842	$98
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	372	487	$13
96372	Injection of drug or substance under skin or into muscle	253	1,793	$11
36415	Insertion of needle into vein for collection of blood sample	904	4,316	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	894	4,486	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	42	1,176	$680,255
Revlimid	Lenalidomide	43	1,176	$624,415
Calquence	Acalabrutinib Maleate	49	1,470	$515,882
Xtandi	Enzalutamide	27	810	$348,028
Jakafi	Ruxolitinib Phosphate	26	780	$345,391

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	24	$569
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	210	$4,116	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$88,317	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alpana A. Desai, M.D.?

Tedicare shows public-source Medicare data for Alpana A. Desai, M.D. (NPI 1477504223), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alpana A. Desai, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alpana A. Desai, M.D.?

Alpana A. Desai, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Alpana A. Desai, M.D. have Open Payments data?

Alpana A. Desai, M.D. has 212 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.